# Ivan Gergel

> Ivan Gergel is a Series B investor at Neuraptive Therapeutics. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Neuraptive Therapeutics](https://shizune.co/investors/profile/neuraptive-therapeutics)
- Total investments: 1
- Last investment: Sep 2023
- Lead investor: 100%
- Last updated: Aug 2026

Ivan Gergel is a Series B investor at Neuraptive Therapeutics. Ivan Gergel is the Executive Chairman of the Board at Neuraptive Therapeutics.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Corsair Pharma | Corsair Pharma is developing transformative solutions to the therapeutic profile of medications and provide superior treatment for patients. | $23M | Series B | Sep 20, 2023 |  |

1 of 1 investments shown.

## Co-investors
- [Junson Capital](https://shizune.co/investors/profile/junson-capital) — VC Fund, 1 deal together
- [Midas Capital](https://shizune.co/investors/profile/midas-capital) — VC Fund, 1 deal together
- [Plaisance Capital](https://shizune.co/investors/profile/plaisance-capital) — VC Fund, 1 deal together
- [Plaisance Capital Management](https://shizune.co/investors/profile/plaisance-capital-management) — VC Fund, 1 deal together
- [Primavera Capital Group](https://shizune.co/investors/profile/primavera-capital) — VC Fund, 1 deal together

## About Neuraptive Therapeutics

VC Fund · Lafayette, United States

Neuraptive was founded to commercialize innovative technology from the University of Texas. The company is dedicated to bringing this technology to patients. It develops novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. Its franchise therapeutics product is designedfor administration during surgery to improve outcomes for patients impacted by acute nerve injury repairs and reconstructive surgical procedures involving peripheral nerves.Founded in 2016, Neuraptive Therapeutics is headquartered in Lafayette, Colorado.

3 contacts available at Neuraptive Therapeutics.

| Name | Title | Profile |
| --- | --- | --- |
| Carter Freeman | CFO | https://shizune.co/investors/profile/carter-freeman |
| David Jackson | Founding Board Member | https://shizune.co/investors/profile/david-m-jackson |
| Ivan Gergel | Chairman | https://shizune.co/investors/profile/ivan-gergel |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### When did Ivan Gergel last invest?

The most recent investment recorded for Ivan Gergel closed in Sep 2023. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co